Research on the Improvement of Intestinal and Immune Functions by Probiotics
ConditionIntestinal Health
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-45
SponsorWecare Probiotics Co., Ltd.
About this trial
Evaluate the effectiveness and safety of Limosilactobacillus fermentum LF61 as a food supplement compared to a placebo in improving intestinal and immune functions in healthy adults.
Eligibility criteria
Qualifiers
Willing to undergo 3 follow-up visits during the intervention period
Be willing to provide blood, urine and stool samples 2 times during the intervention period
Willing to self-administer one of the 7 probiotics (BI45, BBi32, LS97, LB42, LF61, LH76, LR08)/placebo once a day during the intervention period
Good eyesight, can read and write, can wear glasses
Disqualifiers
Digestive diseases, mainly gastrointestinal diseases (celiac disease, ulcerative colitis, Crohn's disease)
Have a serious neurological condition (epilepsy, stroke, severe head trauma, meningitis in the last 10 years, brain surgery, brain tumor, prolonged coma - not including general anaesthesia)
Have received/are receiving treatment for the following mental disorders: alcohol/drug/substance abuse dependence, schizophrenia, psychosis, bipolar disorder
Take medication for depression or low mood
Trial design
Treatments tested in this trial
- Probiotic
- Placebo
Treatment groups
40 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov